Pancreatic ductal adenocarcinoma (PDAC) is the most common primary pancreatic
malignancy, ranking fourth in cancer-related mortality in the United States. Typically, PDAC …

Pancreatic cancer is one of the most lethal malignant neoplasms, with a 1-year survival rate
after diagnosis of 24%, and a 5-year survival rate of only 9%. While this illustrates the …

Pancreatic cancer currently has no subtypes that inform clinical decisions; hence, there
exists an opportunity to rearrange the morphological and molecular taxonomy that guides a …

Abstract Background and Aim Pancreatic cystic lesions (PCLs) are being diagnosed with
increased frequency and have varying neoplastic potential. We conducted this multimodal …

The incidence and mortality of pancreatic ductal adenocarcinoma are growing over time.
The management of patients with pancreatic ductal adenocarcinoma involves a …

Rare malignant pancreatic lesions are systematically reported in this review. The focus is on
the imaging appearance of the rare epithelial pancreatic tumors such as the solid …

BACKGROUND Solid pseudopapillary neoplasms of the pancreas (SPN) share similar
imaging findings with pancreatic ductal adenocarcinoma with cystic changes (PDAC with …

Since rare pancreatic cystic tumors may differ from common pancreatic cystic neoplasms in
terms of treatment plan and prognosis, the differential diagnosis of these diseases is …

Background Solid pseudopapillary neoplasms of the pancreas with hepatic metastases are
infrequent and difficult to diagnose, and treatment is uncertain. Methods A retrospective …

Discussion: It was first described by Franz in 1959 as a papillary tumor of the pancreas, in
2010 it was reclassified as a solid pseudopapillary tumor of low grade of malignancy. They …